dr. wakelee on the rationale for immunotherapy in nsclc
Published 9 years ago • 324 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc
-
1:19
dr. wakelee on combining targeted agents for the treatment of lung cancer
-
1:46
dr. wakelee on single-agent immunotherapy in nsclc
-
1:04
dr. wakelee on the avaperl trial
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
33:15
morning medical update - car-t cell immunotherapy
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
1:13
dr. wakelee discusses the future of lung cancer adjuvant therapy
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
3:23
how personalized immunotherapy saved one woman from cancer
-
1:35
dr. wakelee discusses maintenance therapy for patients with lung cancer
-
6:40
chemotherapy/immunotherapy combinations in lung cancer
-
36:55
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer